

Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size, Share and Growth Outlook 2026: By Test Type (Lateral Flow Immunoassays, Other Point-of-Care Diagnostic Platforms), By Age Group, By Sector Type, Companies to 2034.

<https://marketpublishers.com/r/R909DC4E9E6DEN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: R909DC4E9E6DEN

Abstracts

The global Rapid Point-of-Care Testing For Sickle Cell Anemia Market size is forecast to increase from \$330.5 Million in 2026 to \$774.37 Million in 2034 at a CAGR of 11.23% between 2026 and 2034.

The Rapid Point-of-Care Testing For Sickle Cell Anemia market report provides detailed analysis and outlook of Rapid Point-of-Care Testing For Sickle Cell Anemia segments including By Test Type (Lateral Flow Immunoassays, Other Point-of-Care Diagnostic Platforms), By Age Group (Newborns, Adults and Adolescents), By Sector Type (Government Laboratories, Private Laboratories, Corporate and Public-Private Partnership Labs) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Rapid Point-of-Care Testing for Sickle Cell Anemia Industry Overview

Decentralized Diagnostics and Early Screening Initiatives are Transforming Sickle Cell Disease Detection

The Rapid Point-of-Care Testing for Sickle Cell Anemia industry is experiencing significant advancement as healthcare systems prioritize early diagnosis, decentralized testing, and expanded screening programs for hemoglobin disorders. The increasing global burden of sickle cell disease, particularly across Sub-Saharan Africa, South Asia,

and other resource-limited regions, has accelerated demand for portable, affordable, and highly accurate diagnostic platforms capable of operating outside traditional laboratory settings. Healthcare organizations, public health agencies, and diagnostic manufacturers are focusing on technologies that enable rapid screening, newborn diagnosis, carrier detection, and therapeutic monitoring while minimizing infrastructure requirements. Advances in microfluidics, artificial intelligence, lateral flow diagnostics, and portable analytical systems are expanding access to sickle cell testing and improving disease management outcomes across diverse healthcare environments.

Advanced Point-of-Care Technologies are Expanding Diagnostic Precision Beyond Traditional Screening

The rapid evolution of point-of-care technologies is enabling a transition from simple disease detection toward comprehensive hemoglobin characterization and therapeutic monitoring. Diagnostic developers are increasingly integrating advanced analytical technologies with portable platforms to improve clinical utility and expand testing capabilities. Hemex Health has strengthened this trend through the development of its Gazelle® Hb Variant Test, which combines microchip electrophoresis with integrated artificial intelligence algorithms to quantify multiple hemoglobin variants from finger-prick blood samples within minutes. The platform's recent Breakthrough Device Designation from the U.S. Food and Drug Administration reflects growing recognition of advanced point-of-care technologies capable of supporting disease monitoring and treatment optimization. Comparative clinical studies published in international medical literature further demonstrated that while several rapid tests effectively identify homozygous sickle cell disease, the Gazelle platform uniquely provides accurate quantification of hemoglobin sub-fractions, enabling reliable detection of sickle cell trait and beta-thalassemia carrier states in decentralized healthcare environments.

Resource-Limited Screening Programs and Instrument-Free Diagnostics are Driving Global Market Expansion

The expansion of community-based screening initiatives and public health programs is accelerating adoption of rapid diagnostic technologies across underserved populations. Manufacturers are increasingly developing testing platforms designed to operate without electricity, specialized laboratory infrastructure, or complex logistical support systems. BioMedomics has expanded deployment of its Sickle SCAN® platform through targeted initiatives supporting infant screening programs and premarital genetic counseling services in resource-constrained settings. The lateral flow immunoassay platform enables rapid identification of key hemoglobin variants without requiring instrumentation

or cold-chain storage, addressing critical barriers to diagnostic access in remote regions. These developments reflect broader global healthcare efforts to improve early detection, expand genetic screening coverage, and reduce the clinical burden associated with delayed diagnosis of sickle cell disease and related hemoglobinopathies.

Rapid Point-of-Care Testing For Sickle Cell Anemia Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Rapid Point-of-Care Testing For Sickle Cell Anemia market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- BioMedomics, Inc. (OraSure Technologies), Abbott Laboratories, Roche (Diagnostics), Siemens Healthineers, Danaher Corporation, Becton, Dickinson and Company, QIAGEN N.V., Trinity Biotech plc, bioMérieux, QuidelOrtho. The Rapid Point-of-Care Testing For Sickle Cell Anemia market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Rapid Point-of-Care Testing For Sickle Cell Anemia industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Rapid Point-of-Care Testing For Sickle Cell Anemia Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Rapid Point-of-Care Testing For Sickle Cell Anemia companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Rapid Point-of-Care Testing For Sickle Cell Anemia markets

- Competitive analysis including business description, product analysis, and

financial profiles

Key country specific analysis detailing key factors shaping the short-term and long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Rapid Point-of-Care Testing For Sickle Cell Anemia Market Competitive Benchmarking and Company Analysis

Leading companies in Rapid Point-of-Care Testing For Sickle Cell Anemia industry include- BioMedomics, Inc. (OraSure Technologies), Abbott Laboratories, Roche (Diagnostics), Siemens Healthineers, Danaher Corporation, Becton, Dickinson and Company, QIAGEN N.V., Trinity Biotech plc, bioMérieux, QuidelOrtho. The Rapid Point-of-Care Testing For Sickle Cell Anemia market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Rapid Point-of-Care Testing For Sickle Cell Anemia Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Rapid Point-of-Care Testing For Sickle Cell Anemia market remains one of the strongest-performing segments in the country.

The US Rapid Point-of-Care Testing For Sickle Cell Anemia Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Rapid Point-

of-Care Testing For Sickle Cell Anemia market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Rapid Point-of-Care Testing For Sickle Cell Anemia industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Rapid Point-of-Care Testing For Sickle Cell Anemia markets

Canada's strong Rapid Point-of-Care Testing For Sickle Cell Anemia sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Rapid Point-of-Care Testing For Sickle Cell Anemia market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Rapid Point-of-Care Testing For Sickle Cell Anemia Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Rapid Point-of-Care Testing For Sickle Cell Anemia market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Rapid Point-of-Care Testing For Sickle Cell Anemia population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Rapid Point-of-Care Testing For Sickle Cell Anemia industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Rapid Point-of-Care Testing For Sickle Cell Anemia market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Rapid Point-of-Care Testing For Sickle Cell Anemia sales through 2034

France Rapid Point-of-Care Testing For Sickle Cell Anemia companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Rapid Point-of-Care Testing For Sickle Cell Anemia distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Rapid Point-of-Care Testing For Sickle Cell Anemia Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Rapid Point-of-Care Testing For Sickle Cell Anemia market is undergoing a

structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Rapid Point-of-Care Testing For Sickle Cell Anemia industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Rapid Point-of-Care Testing For Sickle Cell Anemia industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Rapid Point-of-Care Testing For Sickle Cell Anemia Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Rapid Point-of-Care Testing For Sickle Cell Anemia market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Rapid Point-of-Care Testing For Sickle Cell Anemia market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a

sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Rapid Point-of-Care Testing For Sickle Cell Anemia Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Rapid Point-of-Care Testing For Sickle Cell Anemia Market Segmentation

By Test Type

Lateral Flow Immunoassays

Other Point-of-Care Diagnostic Platforms

By Age Group

Newborns

Adults and Adolescents

By Sector Type

Government Laboratories

Private Laboratories

Corporate and Public-Private Partnership Labs

Leading Companies in Rapid Point-of-Care Testing For Sickle Cell Anemia Industry (2026)

BioMedomics, Inc. (OraSure Technologies)

Abbott Laboratories

Roche (Diagnostics)

Siemens Healthineers

Danaher Corporation

Becton, Dickinson and Company

QIAGEN N.V.

Trinity Biotech plc

bioMérieux

QuidelOrtho

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Rapid Point-of-Care Testing For Sickle Cell Anemia Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Rapid Point-of-Care Testing For Sickle Cell Anemia Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Rapid Point-of-Care Testing For Sickle Cell Anemia Markets in 2026
- 3.2. Global Historic and Forecast Rapid Point-of-Care Testing For Sickle Cell Anemia

Market Size Outlook, USD Million, 2021- 2034

3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034

3.4. Market Dynamics

3.4.1. Key Rapid Point-of-Care Testing For Sickle Cell Anemia Market Driving Forces and Their Impact on Market Outlook

3.4.2. Short and Long-Term Trends and Insights Shaping the Future

3.4.3. Potential Rapid Point-of-Care Testing For Sickle Cell Anemia Market Opportunities for Industry Stakeholders

3.4.4. Potential Challenges across Rapid Point-of-Care Testing For Sickle Cell Anemia Value Chain

CHAPTER 4- RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

4.1. Porter's Five Forces Analysis

4.1.1. Bargaining Power of Buyers

4.1.2. Bargaining Power of Suppliers

4.1.3. Threat of Substitutes

4.1.4. Threat of New Entrants

4.1.5. Intensity of Competitive Rivalry

4.1.6. Market Attractiveness Analysis by Segment

4.1.7. Market Attractiveness Analysis by Region

4.2. Competitive Landscape

4.2.1 Market Share Analysis of Leading Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

4.2.2 Recent Strategic Developments

4.2.3 Mergers, Acquisitions, and Partnerships

4.2.4 Product Launches and Innovation Trends

4.2.5 Key Success Factors

4.3. Value Chain Analysis

4.3.1. Key Value Chain Segments

4.3.2. Dominant players by value-chain stage

4.4. SWOT Analysis

4.4.1. Key Strengths and Opportunities

4.4.2. Major Weaknesses and Threats

4.5 Technology Roadmap

4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET OUTLOOK BY SEGMENTS

- 5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
- 5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
- 5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
- By Test Type
 - Lateral Flow Immunoassays
 - Other Point-of-Care Diagnostic Platforms
- By Age Group
 - Newborns
 - Adults and Adolescents
- By Sector Type
 - Government Laboratories
 - Private Laboratories
 - Corporate and Public-Private Partnership Labs

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

- 6.1. Base Case Scenario
 - 6.1.1. Definitions and Insights
 - 6.1.2. Market Size Outlook to 2034
- 6.2. Low Growth Case Scenario
 - 6.2.1. Definitions and Insights
 - 6.2.2. Market Size Outlook to 2034
- 6.3. High Growth Case Scenario
 - 6.3.1. Definitions and Insights
 - 6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET SIZE ANALYSIS AND OUTLOOK

- 7.1. North America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Overview, 2026
- 7.2. Leading Companies Operating in North America
- 7.3. Key Industry Statistics, 2026
- 7.4. North America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Trends and Growth Opportunities to 2034
- 7.5. North America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size

Outlook by Type

7.6. North America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size

Outlook by Application

7.7. North America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size

Outlook by Country

7.8. United States

7.8.1. Key Statistics

7.8.2. The US Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size

Outlook, 2021- 2034

7.8.3. Key Market Drivers and Industry Developments in the US Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

7.9. Canada

7.9.1. Key Statistics

7.9.2. Canada Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size

Outlook, 2021- 2034

7.9.3. Key Market Drivers and Industry Developments in Canada Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

7.10. Mexico

7.10.1. Key Statistics

7.10.2. Mexico Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size

Outlook, 2021- 2034

7.10.3. Key Market Drivers and Industry Developments in Mexico Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

CHAPTER 8- EUROPE RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET SIZE ANALYSIS AND OUTLOOK

8.1. Europe Rapid Point-of-Care Testing For Sickle Cell Anemia Market Overview, 2026

8.2. Leading Companies Operating in Europe

8.3. Key Industry Statistics, 2026

8.4. Europe Rapid Point-of-Care Testing For Sickle Cell Anemia Market Trends and Growth Opportunities to 2034

8.5. Europe Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Type

8.6. Europe Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Application

8.7. Europe Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Country

8.8. Germany

8.8.1. Key Statistics

8.8.2. Germany Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

8.8.3. Key Market Drivers and Industry Developments in Germany Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

8.9. France

8.9.1. Key Statistics

8.9.2. France Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

8.9.3. Key Market Drivers and Industry Developments in France Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

8.10. United Kingdom

8.10.1. Key Statistics

8.10.2. United Kingdom Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

8.10.3. Key Market Drivers and Industry Developments in the UK Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

8.11. Spain

8.11.1. Key Statistics

8.11.2. Spain Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

8.11.3. Key Market Drivers and Industry Developments in Spain Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

8.12. Italy

8.12.1. Key Statistics

8.12.2. Italy Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

8.12.3. Key Market Drivers and Industry Developments in Italy Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

8.13. Rest of Europe

8.13.1. Key Statistics

8.13.2. Rest of Europe Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

CHAPTER 9- ASIA PACIFIC RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET SIZE ANALYSIS AND OUTLOOK

- 9.1. Asia Pacific Rapid Point-of-Care Testing For Sickle Cell Anemia Market Overview, 2026
- 9.2. Leading Companies Operating in Asia Pacific
- 9.3. Key Industry Statistics, 2026
- 9.4. Asia Pacific Rapid Point-of-Care Testing For Sickle Cell Anemia Market Trends and Growth Opportunities to 2034
- 9.5. Asia Pacific Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Type
- 9.6. Asia Pacific Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Application
- 9.7. Asia Pacific Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Country
- 9.8. China
 - 9.8.1. Key Statistics
 - 9.8.2. China Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034
 - 9.8.3. Key Market Drivers and Industry Developments in China Rapid Point-of-Care Testing For Sickle Cell Anemia Companies
- 9.9. Japan
 - 9.9.1. Key Statistics
 - 9.9.2. Japan Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034
 - 9.9.3. Key Market Drivers and Industry Developments in Japan Rapid Point-of-Care Testing For Sickle Cell Anemia Companies
- 9.10. India
 - 9.10.1. Key Statistics
 - 9.10.2. India Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034
 - 9.10.3. Key Market Drivers and Industry Developments in India Rapid Point-of-Care Testing For Sickle Cell Anemia Companies
- 9.11. South Korea
 - 9.11.1. Key Statistics
 - 9.11.2. South Korea Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034
 - 9.11.3. Key Market Drivers and Industry Developments in South Korea Rapid Point-of-Care Testing For Sickle Cell Anemia Companies
- 9.12. Australia
 - 9.12.1. Key Statistics
 - 9.12.2. Australia Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size

Outlook, 2021- 2034

9.12.3. Key Market Drivers and Industry Developments in Australia Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

9.13. Southeast Asia

9.13.1. Key Statistics

9.13.2. Southeast Asia Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET SIZE ANALYSIS AND OUTLOOK

10.1. South and Central America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Overview, 2026

10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Trends and Growth Opportunities to 2034

10.5. South and Central America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Type

10.6. South and Central America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Application

10.7. South and Central America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Country

10.8. Brazil

10.8.1. Key Statistics

10.8.2. Brazil Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

10.8.3. Key Market Drivers and Industry Developments in Brazil Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

10.9. Argentina

10.9.1. Key Statistics

10.9.2. Argentina Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

10.9.3. Key Market Drivers and Industry Developments in Argentina Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

10.10. Rest of Latin America

10.10.1. Key Statistics

10.10.2. Rest of Latin America Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

CHAPTER 11- MIDDLE EAST AND AFRICA RAPID POINT-OF-CARE TESTING FOR SICKLE CELL ANEMIA MARKET SIZE ANALYSIS AND OUTLOOK

11.1. Middle East and Africa Rapid Point-of-Care Testing For Sickle Cell Anemia Market Overview, 2026

11.2. Leading Companies Operating in Middle East and Africa

11.3. Key Industry Statistics, 2026

11.4. Middle East and Africa Rapid Point-of-Care Testing For Sickle Cell Anemia Market Trends and Growth Opportunities to 2034

11.5. Middle East and Africa Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Type

11.6. Middle East and Africa Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Application

11.7. Middle East and Africa Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook by Country

11.8. Saudi Arabia

11.8.1. Key Statistics

11.8.2. Saudi Arabia Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

11.9. United Arab Emirates

11.9.1. Key Statistics

11.9.2. The UAE Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

11.9.3. Key Market Drivers and Industry Developments in the UAE Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

11.10. Africa

11.10.1. Key Statistics

11.10.2. Africa Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Rapid Point-of-Care Testing For Sickle Cell Anemia Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Rapid Point-of-Care Testing For Sickle Cell Anemia Industry

BioMedomix, Inc. (OraSure Technologies)

Abbott Laboratories

Roche (Diagnostics)

Siemens Healthineers

Danaher Corporation

Becton, Dickinson and Company

QIAGEN N.V.

Trinity Biotech plc

bioMérieux

QuidelOrtho

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size, Share and Growth Outlook 2026: By Test Type (Lateral Flow Immunoassays, Other Point-of-Care Diagnostic Platforms), By Age Group, By Sector Type, Companies to 2034.

Product link: <https://marketpublishers.com/r/R909DC4E9E6DEN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R909DC4E9E6DEN.html>